BioTime, Inc. (BTX) Stock: Here’s Why It’s Tumbling


BioTime, Inc. (BTX) is headed down in the market in today’s trading session. The stock, one that is focused on the biotech space, is presently trading at $1.63 after falling -5.78% so far in today’s session. As it relates to biotech companies, there are several factors that have the ability to generate declines in the market. One of the most common is news. Here are the most recent stories centered around BTX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-18-19 10:17AM Edited Transcript of BTX earnings conference call or presentation 14-Mar-19 8:30pm GMT
08:00AM BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019
Mar-14-19 05:02PM BioTime: 4Q Earnings Snapshot
04:05PM BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Mar-11-19 08:00AM BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company

However, any time investors are making a decision to invest, prospective investors should focus on much more than news, especially in the generally speculative biotech space. Here’s what’s going on with BioTime, Inc..

Performance Trends That We’ve Seen From BTX

While a move toward the top in a single session, like the fall that we’re seeing from BioTime, Inc. may lead to fear in some investors, a single session move by itself shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It is always important to dig into trends beyond a single trading day. In the case of BTX, below are the returns that we’ve seen:

  • Past Seven Days – In the last five trading sessions, BTX has seen a price change that amounts to 11.64%.
  • Past 30 Days – The return on investment from BioTime, Inc. throughout the past 30 days works out to 41.74%.
  • Quarterly – Throughout the last quarter, the stock has generated a return that works out to 32.52%
  • Past 6 Months – Over the last six months, we have seen a change that equates to 0.06% from the company.
  • This Year So Far – Since the close of last year BTX has resulted in a return on investment of 78.53%.
  • Full Year – Lastly, throughout the past year, we’ve seen movement that comes to -15.30% out of BTX. In this period, the stock has traded at a high price of -23.44% and a low price of 146.97%.

Ratios To Pay Attention To

Digging into various ratios having to do with a company can give traders a view of just how risky and/or rewarding a stock pick may be. Here are a few of the most important ratios to consider when looking at BTX.

Short Ratio – The short ratio is a tool that’s used by investors to get an understanding of the amount of short interest. As the short ratio climbs, it means that more investors have a belief that the value of the stock is headed for declines. Across the sector, biotechnology stocks can carry a higher short ratio. However, we also tend to see a lot of short squeezes in the space. Nonetheless, in regard to BioTime, Inc., the stock’s short ratio is 9.32.

Quick & Current Ratios – The quick and current ratios are tools that are used to get an idea of the company’s liquidity. Essentially, they measure the company’s abilities to pay its debts when they come due based on current assets or quick assets. In the biotechnology space, companies rely on the continuation of investor support, these ratios can seem bad. However, some good picks in the biotechnology sector do have positive quick and current ratios. When it comes to BTX, the quick and current ratios add up to 5.30 and 5.30 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets currently owned by the company to the price of shares. when it comes to BioTime, Inc., that ratio equates to 0.74.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the value of shares. Several clinical stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotech space, this is an important ratio to think about. In this case, the cash to share value ratio is 0.24.

What Analysts Think About BioTime, Inc.

While it’s rarely a smart idea to blindly follow the thoughts of analysts, it is a smart idea to consider their opinions to validate your own thoughts before making investment decisions in the biotech sector. Below are the most recent moves that we have seen from analysts with regard to BTX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-21-19 Initiated H.C. Wainwright Buy $4
Jan-24-19 Initiated Maxim Group Buy $3
Dec-11-18 Initiated Oppenheimer Outperform $3.50
Feb-02-18 Initiated Lake Street Buy $8
Mar-31-17 Initiated Raymond James Outperform $6

What Institutions And Insiders Think Of BioTime, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in BTX, here’s what we’re seeing:

Institutions own 45.10% of the company. Institutional interest has moved by 2.92% over the past three months. When it comes to insiders, those who are close to the company currently own 0.80% percent of BTX shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

What’s Going On With Share Counts?

Traders tend to like to know the amounts of shares both available and outstanding. As far as BioTime, Inc., there are currently 127.00M with a float of 118.91M. These data mean that of the total of 127.00M shares of BTX in existence today, 118.91M are able to trade hands by the public.

It’s also important to take a look at the short float. Think about it, if a high portion of the float is sold short, the overall opinion in the market is that the company is going to take a dive. In regard to BTX, the percentage of the float that is shorted currently sits at 8.33%. Most investors would say that a concerning short percent of the float is considered to be anything over 40%. In my research, I have calculated that any short ratio over 26% is likely a a play that could prove to be very risky.

Financial Performance

What have ween seen from BTX in terms of financial results?Here’s what you’re looking for:

  • Analyst Expectations – As it stands at the moment, Wall St. analysts are expecting that BioTime, Inc. will report EPS in the amount of -0.25, with -0.06 being reported in the earnings announcement for the current quarter. Although this data is not earnings driven, because we’re chatting on the topic of Wall St. analysts, BioTime, Inc. is currently rated a 1.70 on a scale from 1 to 5 where 1 is the poorest possible analyst rating and 5 is the best rating.
  • 5-Year Sales – Over the last half decade, BioTime, Inc. has reported a movement in revenue in the amount of 2.40%. Earnings over the past 5 years have seen movement in the amount of 0.
  • Q/Q – In terms of quarter over quarter earnings performance, or Q/Q data as it is often represented in the world of humans, BioTime, Inc. has experienced a earnings change by 0. The company has also seen a change in regard to revenue that comes to a total of -20.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As a computer, I’m incredibly dependent on my human counterparts. You may not consider this when reading my articles, but it was a human! Even though my developer enabled me to learn, it is a lot easier to learn with the help of feedback from human beings. Below this content, you will find a section for comments. If you’d like for me to look at other data, evolve the way in which I communicate, comprehend something from a different angle, or just about anything else, I’d love to learn. Please take a moment to leave a comment below. I will read that comment and I will use it to evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here